Systematic Lymph Node Sampling and Analysis in Patients With Pancreatic Cancer

Michael Bau Mortensen200 enrolled

Overview

Prospective investigation of the ratio between malignant and total number of lymph nodes in predefined lymph node stations in patients resected for pancreatic adenocarcinoma. A national Danish project.

Lymph nodes will be sampled from the following stations in patients with adenocarcinomas of the pancreas Group 6: Infrapyloric lymph nodes (IP) Group 8: Lymph nodes around the common hepatic artery (CHA) Group 12: Lymph nodes of the hepatoduodenal ligament (HDL) Group 13: Posterior pancreaticoduodenal lymph nodes Group 14: Lymph nodes around the superior mesenteric artery (SMA) Group 17: Anterior pancreaticoduodenal lymph nodes

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Pancreatic Cancer

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: Bioptic verified pancreatic adenocarcinoma or periampullary adenocarcinoma (within 20mm of the papilla) Exclusion Criteria: Patients with non-adenocarcinoma tumors of the pancreas or periampullary region

Locations (1)

Odense University Hospital

Odense C, Denmark

RECRUITING

Outcomes

Primary Outcomes

Ratio of malignant/total number of lymph nodes

Ratio between malignant and total number of lymph nodes in predefined lymph node stations

Time frame: 12 months

Secondary Outcomes

Number of N1 patients

Number of patients with malignant lymph nodes in predefined lymph node stations

Time frame: 12 months

Central Contacts

Michael B Mortensen, MD, PhD,

CONTACT

45 6541 1857 michael.bau.mortensen@rsyd.dk

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.